Kenvue Inc. (KVUE) to Issue Quarterly Dividend of $0.21 on February 26th

Kenvue Inc. (NYSE:KVUE) announced a quarterly dividend on Thursday, January 16th,Wall Street Journal reports. Shareholders of record on Wednesday, February 12th will be given a dividend of 0.205 per share on Wednesday, February 26th. This represents a $0.82 annualized dividend and a yield of 3.89%. The ex-dividend date of this dividend is Wednesday, February 12th.

Kenvue has a payout ratio of 63.1% indicating that its dividend is sufficiently covered by earnings. Equities research analysts expect Kenvue to earn $1.20 per share next year, which means the company should continue to be able to cover its $0.82 annual dividend with an expected future payout ratio of 68.3%.

Kenvue Stock Performance

Shares of KVUE stock opened at $21.11 on Friday. Kenvue has a 52-week low of $17.67 and a 52-week high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The stock has a market cap of $40.46 billion, a PE ratio of 38.37, a price-to-earnings-growth ratio of 1.99 and a beta of 1.46. The business has a 50-day simple moving average of $22.42 and a 200-day simple moving average of $21.66.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating the consensus estimate of $0.27 by $0.01. The firm had revenue of $3.90 billion during the quarter, compared to analyst estimates of $3.92 billion. Kenvue had a net margin of 6.88% and a return on equity of 21.43%. The business’s quarterly revenue was down .4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.31 EPS. On average, equities analysts expect that Kenvue will post 1.14 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on KVUE. Bank of America increased their target price on Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. Citigroup decreased their price objective on shares of Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a report on Wednesday. Barclays cut their target price on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research note on Friday. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a “buy” rating to a “hold” rating and decreased their price target for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, UBS Group reduced their target price on Kenvue from $24.00 to $23.00 and set a “neutral” rating for the company in a report on Thursday. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $23.08.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.